Embodiments of the present application relate to polymers used as polymeric polyvalent hubs for liquid phase oligonucleotide synthesis. Methods for making an oligonucleotide by liquid phase oligonucleotide synthesis using the polymers are also provided.

The present invention is broadly concerned with materials, processes, and structures that allow an underlayer to be imaged directly using conventional lithography, thus avoiding the photoresist processing steps required by prior art directed self-assembly (DSA) processes. The underlayers can be tailored to favor a selected block of the DSA block co-polymers (BCP), depending on the pattern, and can be formulated either to initially be neutral to the BCP and switch to non-neutral after photoexposure, or can initially be non-neutral to the BCP and switch to neutral after exposure. These materials allow fast crosslinking to achieve solvent resistance and possess good thermal stability.

The present invention is broadly concerned with materials, processes, and structures that allow an underlayer to be imaged directly using conventional lithography, thus avoiding the photoresist processing steps required by prior art directed self-assembly (DSA) processes. The underlayers can be tailored to favor a selected block of the DSA block co-polymers (BCP), depending on the pattern, and can be formulated either to initially be neutral to the BCP and switch to non-neutral after photoexposure, or can initially be non-neutral to the BCP and switch to neutral after exposure. These materials allow fast crosslinking to achieve solvent resistance and possess good thermal stability.

Surface-modified nanoparticles wherein each nanoparticle includes an inorganic core and surface modifying groups, wherein the surface modifying groups include at least one triorganoborane-amine complex having the structure ZNHR.sup.1B(R.sup.2).sub.3 wherein: Z is a divalent organic group; R.sup.1 is H or an organic group; and each R.sup.2 is independently an organic group bound to the boron atom through a carbon atom. The inorganic core is typically an inorganic oxide core, e.g., silica, zirconia, or alumina.

Surface-modified nanoparticles wherein each nanoparticle includes an inorganic core and surface modifying groups, wherein the surface modifying groups include at least one triorganoborane-amine complex having the structure ZNHR.sup.1B(R.sup.2).sub.3 wherein: Z is a divalent organic group; R.sup.1 is H or an organic group; and each R.sup.2 is independently an organic group bound to the boron atom through a carbon atom. The inorganic core is typically an inorganic oxide core, e.g., silica, zirconia, or alumina.

Provided is a liquid developer that gives a high image density, has a high resistance, suppresses the appearance of image blurring, can be reused, is readily cured by ultraviolet radiation, and can accommodate higher process speeds. This liquid developer contains a carrier liquid, a toner particle insoluble in the carrier liquid, and a compound with the following formula (1)

##STR00001##

[In formula (1), R.sub.1 and R.sub.2 each independently represent an alkyl group having at least 13 and not more than 23 carbons.].

Provided is a liquid developer that gives a high image density, has a high resistance, suppresses the appearance of image blurring, can be reused, is readily cured by ultraviolet radiation, and can accommodate higher process speeds. This liquid developer contains a carrier liquid, a toner particle insoluble in the carrier liquid, and a compound with the following formula (1)

##STR00001##

[In formula (1), R.sub.1 and R.sub.2 each independently represent an alkyl group having at least 13 and not more than 23 carbons.].

A purpose of the present invention is to provide a siloxane suitable for preparing a medical material and a method for preparing the compound. The present invention provides a siloxane represented by the formula (1), wherein R.sup.1 is a hydrogen atom or a methyl group, R.sup.2 is a monovalent hydrocarbon group having 1 to 6 carbon atoms, L is a divalent hydrocarbon group which has 2 to 10 carbon atoms and may have one or more ether bonds, and A is a (poly)siloxane group represented by the formula (2) or (3), wherein n is an integer of 1 to 100, a is an integer of 0 to 10, b is an integer of 0 to 10, and c is an integer of 0 to 10, provided that a+b+c is 2 or more, and R is, independently of each other, a monovalent hydrocarbon group having 1 to 10 carbon atoms. The present invention further provides a method for preparing the siloxane, a polymer comprising recurring units derived from the siloxane, and a medical material, particularly an ophthalmic device, comprising the aforesaid polymer.

A purpose of the present invention is to provide a siloxane suitable for preparing a medical material and a method for preparing the compound. The present invention provides a siloxane represented by the formula (1), wherein R.sup.1 is a hydrogen atom or a methyl group, R.sup.2 is a monovalent hydrocarbon group having 1 to 6 carbon atoms, L is a divalent hydrocarbon group which has 2 to 10 carbon atoms and may have one or more ether bonds, and A is a (poly)siloxane group represented by the formula (2) or (3), wherein n is an integer of 1 to 100, a is an integer of 0 to 10, b is an integer of 0 to 10, and c is an integer of 0 to 10, provided that a+b+c is 2 or more, and R is, independently of each other, a monovalent hydrocarbon group having 1 to 10 carbon atoms. The present invention further provides a method for preparing the siloxane, a polymer comprising recurring units derived from the siloxane, and a medical material, particularly an ophthalmic device, comprising the aforesaid polymer.

Embodiments of the present application relate to polymers used as polymeric polyvalent hubs for liquid phase oligonucleotide synthesis. Methods for making an oligonucleotide by liquid phase oligonucleotide synthesis using the polymers are also provided.